...
首页> 外文期刊>Orthopaedic Journal of Sports Medicine >POSTOPERATIVE AND POST-DISCHARGE PAIN OUTCOMES AND OPIOID REQUIREMENTS IN PEDIATRIC ARTHROSCOPIC ACL RECONSTRUCTION AND/OR MENISCUS PROCEDURES MANAGED WITH PERIPHERAL NERVE BLOCKADE
【24h】

POSTOPERATIVE AND POST-DISCHARGE PAIN OUTCOMES AND OPIOID REQUIREMENTS IN PEDIATRIC ARTHROSCOPIC ACL RECONSTRUCTION AND/OR MENISCUS PROCEDURES MANAGED WITH PERIPHERAL NERVE BLOCKADE

机译:术后和后排放后疼痛结果和小儿关节镜ACL重建和/或用周围神经阻塞管理的弯月面手术

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Peripheral nerve blockade (PNB) can be a useful component of a multimodal analgesia strategy for managing pain after knee arthroscopy and supports goals of improved opioid stewardship given the national crisis. However, the impact of PNB on short-term recovery in pediatric patients undergoing knee arthroscopy for anterior cruciate ligament (ACL) reconstruction and meniscus surgery (repair or resection) has not been well characterized. This prospective study presents patient outcomes following discharge home in pediatric patients undergoing arthroscopic ACL and/or meniscus procedures managed with PNB. Methods: This is a single-center, single-surgeon prospective observational study conducted over a three year period. We characterized 72-hour postoperative outcomes including pain scores, return of sensation to affected limb, analgesic use (NSAID’s and opioids), readmission rate, and activities of daily living via telephone survey. In addition, retrospective chart review was conducted to obtain perioperative and anesthesia details. Results for surgery groups were analyzed using descriptive and Pearson correlations using SPSS v24. Results: We collected data on 47 patients undergoing ACL reconstruction with or without meniscus surgery (n=18) or meniscus surgery only (n=29). The mean ages for each group were 16.0 ± 1.4 years and 15.7 ± 1.4 years, with 13/18 and 18/29 females, respectively. At 72 hours post-surgery, there were no readmissions or complications related to pain. PACU pain scores and follow up data from the post discharge survey is presented in Table 1. Median and interquartile ranges (IQR) of maximum PACU pain ratings were 0 (0.0-3.5) for the ACL group and 0 (0.0-2.5) for the meniscus-only group. Median (IQR) for pain score at 72 hours post-surgery was 2.5 (1.0-5.0) and 5 (3.0-6.0) for the ACL and meniscus-only groups only. For the meniscus-only group, maximum PACU pain scores correlated with 72-hour pain score (r=0.431, p=0.025) but not for the ACL group (r=0.418, 0.084). PACU pain scores and follow up data from the post discharge survey is presented in Table 2. A majority of patients continued to require opioids (45/47) and NSAIDs (46/47) at 72 hours post-surgery, but the number of daily opioid doses taken decreased each day postoperatively. Over 93% of patients could ambulate and shower at 72 hours post-surgery and sensation to affected limbs returned most commonly on postoperative day 1 in both groups. Conclusions / Significance: Regional nerve block appears to be an effective and safe analgesic strategy for pediatric arthroscopic ACL and meniscus procedures, with no short-term complications or readmissions related to pain in our cohort and all patients showing clinically minor levels of pain post-discharge. Future prospective investigation is needed to characterize long-term pain outcomes and opioid use in this surgical population in direct comparison to patients not receiving PNB. Table 2: 72-Hour Postoperative Follow-up Group A: ACL ± Meniscal Surgery Group B: Meniscal Surgery PACU Maximum Pain Score (Median Interquartile Range (25 ~(th)–75 ~(th))) 0.0 (0.0-3.5) 0.0 (0.0-2.5) 72-Hour Pain Score (Median Interquartile Range (25 ~(th)–75 ~(th))) 2.5 (1.0-5.0) 5.0 (3.0-6.0) Day Sensation Returned DOS 3 / 18 4 / 29 POD1 12 / 18 19 / 29 POD2 3 / 18 6 / 29 POD3 0 / 18 0/29 Readmission 0 / 18 0/29 ADL’s Shower 18 / 18 26 /29 Ambulation 17 / 18 28 / 29 Ambulation with Crutches 17 / 18 26 / 29 Using NSAID? 18 / 18 27 / 28 NSAlD Type Ibuprofen 17 / 18 28 / 29 Naproxen 1 / 18 0 / 29 Rx/OTC Rx 17 / 18 27 / 29 OTC 1 / 18 2 / 29 NSAID Dose Number DOS 4.0 (3.75-4.0) 4.0 (4.0-4.0) POD1 4.0 (4.0-4.0) 4.0 (4.0-4.0) POD2 4.0 (3.85-4.0) 4.0 (4.0-4.0) POD3 4.0 (3.0-5.0) 4.0 (4.0-4.0) NSAID-Related Side Effects Indigestion 2 / 18 1 / 29 None 15 / 18 27 / 29 Using Opioid? 18 / 18 27 / 29 Opioid Type Oxycodone 18 / 18 26 / 29 Hydrocodone 0 / 18 1 / 29 Number of Opioid Doses (Median, Interquartile Range) DOS 6.0 (4.0-6.0) 6.0 (4.0-6.0) POD1 6.0 (4.0-6.0) 4.8 (4.0-6.0) POD2 4.0 (1.75-6.0) 4.0 (2.0-6.0) POD3 4.0 (0.0-6.0) 1.0 (0.0-4.8) Opioid-Related Side Effects. Constipation 4 / 18 6 / 29 Dizziness 1 / 18 2 / 29 Indigestion 2 / 18 2 / 29 Nausea/Vomiting 3 / 18 1 / 29 Itchiness 4 / 18 0 / 29
机译:背景:外周神经阻滞(PNB)可以是用于在膝关节视镜检查后进行疼痛的多模式镇痛策略的有用组分,并支持鉴于国家危机,支持改善的阿片类药管的目标。然而,PNB对接受膝关节视镜(ACL)重建和弯月球手术(修复或切除)进行膝关节镜检查的儿科患者短期回收的影响并未得到很好的表征。该预期研究提出了在接受关节镜ACL和/或PNB管理的弯月面手术的儿科患者中的患者之后提出患者结果。方法:这是一项三年内的单一外科医生前瞻性观察研究。我们以疼痛评分为特征在内的72小时术后结果,患有受影响的肢体,镇痛药(NSAID和阿片类药物),阅览室通过电话调查恢复。此外,还进行了回顾性图表评审,以获得围手术期和麻醉细节。使用SPSS V24使用描述性和Pearson相关性分析手术组的结果。结果:我们收集了47名接受ACL重建的数据,或没有弯月球手术(n = 18)或弯月球手术(n = 29)。每组的平均年龄分别为16.0±1.4岁和15.7±1.4岁,分别为13/18和18/29雌性。在手术后72小时,没有与疼痛有关的再生或并发症。 PACU疼痛评分和后续放电调查的后续数据呈现在表1.最大PACU疼痛评级的中位数和间条态范围(IQR)为ACL组的0(0.0-3.5),为0(0.0-2.5)营念群体。疼痛评分的中位数(IQR)在手术后72小时为2.5(1.0-5.0)和5(3.0-6.0),只有ACL和营数只有液晶组。对于仅疯狂的群体,最高PACU疼痛评分与72小时疼痛评分相关(r = 0.431,p = 0.025),但不适用于ACL组(r = 0.418,0.084)。 PACU疼痛评分和从后放电调查的跟进数据显示在表2中。大多数患者继续在手术后72小时内持续需要阿片类药物(45/47)和NSAIDs(46/47),但每天的数量阿片类剂量术后每天减少。超过93%的患者可以在手术后72小时和淋浴和淋浴到两组术后第1天最常见的受影响的四肢。结论/意义:区域神经阻滞似乎是儿科关节镜ACL和弯月面手术的有效和安全的镇痛策略,没有与我们的队列中的疼痛有关的短期并发症,并且所有患者出院后显示出临床较小的疼痛水平。需要未来的前瞻性调查,以表征在这种手术人群中的长期疼痛结果和阿片类药物直接与未接受PNB的患者直接比较。表2:72小时术后随访组A:ACL±半月板手术组:半月板手术PACU最大疼痛评分(中位数间位范围(25〜(Th)-75〜(Th)))0.0(0.0-3.5) 0.0(0.0-2.5)72小时疼痛评分(中位数间隙范围(25〜(TH)-75〜(TH)))2.5(1.0-5.0)5.0(3.0-6.0)日感性返回DOS 3/18 4 / 29 Pod1 12/18 19/29 Pod2 3/18 6/29 Pod3 0/18 0/29 Readmossion 0/18 0/29 Adl's淋浴18/29 26/29救援17/18 28/29带拐杖17/18的救护车26/29使用NSAID? 18/18 27/28 NSALD型IBuprofen 17/18 28/29 Naproxen 1/18 0/29 Rx / OTC RX 17/18 27/29 OTC 1/18 2/29 NSAID剂量编号DOS 4.0(3.75-4.0)4.0 (4.0-4.0)POD1 4.0(4.0-4.0)4.0(4.0-4.0)POD2 4.0(3.85-4.0)4.0(4.0-4.0)POD3 4.0(3.0-5.0)4.0(4.0-4.0)NSAID相关的副作用消化不良2/18 1/29无15/18 27/27使用阿片类药物? 18/18 / 29 27/29阿片类羟基酮型羟氢酮18/18 26/29水电酮0/18 1/22阿片类药物(中位数,间隔范围)DOS 6.0(4.0-6.0)6.0(4.0-6.0)POD1 6.0(4.0- 6.0)4.8(4.0-6.0)POD2 4.0(1.75-6.0)4.0(2.0-6.0)POD3 4.0(0.0-6.0)1.0(0.0-4.8)阿片类药物相关的副作用。便秘4/18 6/29眩晕1/18 2/29消化不良2/18 2/29恶心/呕吐3/18 1/29瘙痒4/18 0/29

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号